Concepedia

Risk of post‐operative surgical site infections after vedolizumab vs anti‐tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease

K.T. Park, Lindsay A. Sceats, Melody S. Dehghan, Amber W. Trickey, Ana Vanessa A Wren, Jessie J. Wong, Rachel Bensen, Berkeley N. Limketkai, Kian Keyashian, Cindy Kin

Alimentary Pharmacology & Therapeutics · 2018 · 29 citations · 32 references

DOIFull text

Open access

Abstract

In the largest, risk-adjusted cohort analysis to date, perioperative exposure to VDZ therapy was not associated with a significantly higher risk of developing an SSI compared to TNFi therapy.

References

32

Validation of a combined comorbidity index

Mary E. Charlson, Ted P. Szatrowski, Janey C. Peterson et al. · Journal of Clinical Epidemiology · 1994 · 6.4K citations

, , +6

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · New England Journal of Medicine · 2013 · 2.8K citations · Full text

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn, Brian G. Feagan, Paul Rutgeerts et al. · New England Journal of Medicine · 2013 · 2.6K citations · Full text

Prevalence of Malnutrition in General Medical Patients

Bruce R. Bistrian · JAMA · 1976 · 917 citations

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Jean‐Frédéric Colombel, Bruce E. Sands, Paul Rutgeerts et al. · Gut · 2016 · 789 citations · Full text